A comparative costs analysis of brachytherapy and Radical Retropubic Prostatectomy therapies for clinically localized prostate cancer

Gianino, Maria Michela; Galzerano, Mario; Minniti, Davide; Novi, Cinzia Di; Martin, Barbara; Davini, Ottavio; Barbaro, Silvana

doi:10.1017/s0266462309990043

Cited by 11 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent statistics estimated 233,00 new cases and 29,480 deaths occurred from prostate cancer in the United States in 2014 [1]. Prostate cancer mortality has been declining but therapy and surgery expenses are still very high [2, 3]. Conventional chemotherapy results in off-target effects: anti-cancer drug(s) cause damage to healthy rapidly dividing cells and thus patients often experience normal organ toxicity [4].…”

Section: Introductionmentioning

confidence: 99%

Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer

Yallapu¹,

Khan²,

Maher³

et al. 2014

Biomaterials

235

153

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed cancer disease in men in the Unites States and its management remains challenge in everyday oncology practice. Thus, advanced therapeutic strategies are required to treat prostate cancer patients. Curcumin (CUR) is a promising anticancer agent for various cancer types. The objective of this study was to evaluate therapeutic potential of novel poly(lactic-co-glycolic acid)- CUR nanoparticles (PLGA-CUR NPs) for prostate cancer treatment. Our results indicate that PLGA-CUR NPs efficiently internalize in prostate cancer cells and release biologically active CUR in cytosolic compartment of cells for effective therapeutic activity. Cell proliferation (MTS), clonogenic, and Western blot analyses reveal that PLGA-CUR NPs can effectively inhibit proliferation and colony formation ability of prostate cancer cells than free CUR. PLGA-CUR NPs showed superior tumor regression compared to CUR in xenograft mice. Further investigations reveal that PLGA-CUR NPs inhibit nuclear β-catenin and AR expression in cells and in tumor xenograft tissues. It also suppresses STAT3 and AKT phosphorylation and leads to apoptosis via inhibition of key anti-apoptotic proteins, MCL-1, Bcl-xL and caused induction of PARP cleavage. Additionally, PLGA-CUR NPs significant downregulation of oncogenic miR21 and up-regulation of miR-205 was observed with PLGA-CUR NPs treatment as determined by RT-PCR and in situ hybridization analyses. A superior anti-cancer potential was attained with PSMA antibody conjugated PLGA-CUR NPs in prostate cancer cells and a significant tumor targeting of 131I labelled PSMA antibody was achieved with PLGA-CUR NPs in prostate cancer xenograft mice model. In conclusion, PLGA-CUR NPs can significantly accumulate and exhibit superior anticancer activity in prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer

Yallapu¹,

Khan²,

Maher³

et al. 2014

Biomaterials

235

153

View full text Add to dashboard Cite

show abstract

“…This statistics is rapidly increasing with every passing year. PCa has surpassed heart disease as the top killer of men over the age of 85 years [ 2 , 3 ]. Although the mortality rate due to prostate gland cancer is decreasing, the cost of therapy and surgery makes it costly for a common man [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Highly Stable PEGylated Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for the Effective Delivery of Docetaxel in Prostate Cancers

2016

View full text Add to dashboard Cite

In the present study, a highly stable luteinizing-hormone-releasing hormone (LHRH)-conjugated PEGylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles were developed for the successful treatment of prostate cancers. We have demonstrated that a unique combination of targeted drug delivery and controlled drug release is effective against prostate cancer therapy. The docetaxel (DTX)/PLGA-LHRH micelles possessed a uniform spherical shape with an average diameter of ~170 nm. The micelles exhibited a controlled drug release for up to 96 h which can minimize the non-specific systemic spread of toxic drugs during circulation while maximizing the efficiency of tumor-targeted drug delivery. The LHRH-conjugated micelles showed enhanced cellular uptake and exhibited significantly higher cytotoxicity against LNCaP cancer cells. We have showed that PLGA-LHRH induced greater caspase-3 activity indicating its superior apoptosis potential. Consistently, LHRH-conjugated micelles induced threefold and twofold higher G2/M phase arrest than compared to free DTX or PLGA NP-treated groups. Overall, results indicate that use of LHRH-conjugated nanocarriers may potentially be an effective nanocarrier to effectively treat prostate cancer.

show abstract

“…The treatment options for prostate cancer that are commonly used at present are chemotherapy, surgical intervention and ionizing radiation therapy. However none of these therapeutic approaches effectively controls tumor proliferation, with 20-30% reoccurrence rates in patients (1)(2)(3). In this regard, BLT, an FDA-approved antineoplastic hormonal agent is primarily indicated for the treatment of prostate cancer (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Statistically, prostate cancer has overtaken heart diseases and lung disorders in old people as a cause of mortality. According to estimates, >200,000 new cases of prostate cancer were reported with >30,000 mortalities during the year 2013 (2,3). A similar or higher number of cases has been projected for the year 2014 (4).…”

Section: Introductionmentioning

confidence: 97%

Anticancer activity of bicalutamide-loaded PLGA nanoparticles in prostate cancers

Guo

Ren

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men in western and most developing countries. Bicalutamide (BLT) is an antineoplastic hormonal agent primarily used in the treatment of locally advanced and metastatic prostate cancers. In the present study, the aim was to develop a nanotechnology-based delivery system to target prostate cancer cells. This involved the development of a BLT-loaded poly(D,L-lactide-co-glycolide) PLGA (PLGA-BLT) nanoparticulate system in an attempt to improve the therapeutic efficacy of BLT in prostate cancer and to mitigate its toxicity. Nanosized particles with a uniform size distribution and spherical shape were developed. PLGA-BLT showed a pronounced cytotoxic effect on LNCaP and C4-2 cancer cells. The superior cell-killing effect of the nanoparticles may be attributable to their sustained drug-release characteristics and high cellular internalization. PLGA-BLT was also found to significantly inhibit colony formation in the two cell lines. Furthermore, the caspase-3 activity of PLGA-BLT treated cancer cells was enhanced, indicating the cell apoptosis-inducing potential of PLGA-BLT. Overall, these results suggest that nanotechnology-based formulations of BLT exhibit superior anticancer activity and have enormous potential in the treatment of prostate cancers.

show abstract

A comparative costs analysis of brachytherapy and Radical Retropubic Prostatectomy therapies for clinically localized prostate cancer

Abstract: Published studies of costing data of BT and RRP do not provide clear-cut evidence for a conclusion about which treatment may be more effective from an economic point of view.

Cited by 11 publications

References 18 publications

Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer

Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer

Highly Stable PEGylated Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for the Effective Delivery of Docetaxel in Prostate Cancers

Anticancer activity of bicalutamide-loaded PLGA nanoparticles in prostate cancers

Contact Info

Product

Resources

About